TradingFloor AI · Stock Terminal

RYTM - Ticker AI Digest

Rhythm Pharmaceuticals Inc 📰 1
107.17000000 | Today -4.76% ●
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
Rhythm Pharmaceuticals Inc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
RYTM Data 2026-08-31 Preview Mode
Core Deck
Deep Dive Modules
Home

Digested News

Today's Catalysts (RYTM) 1
RYTM 12:22
Rhythm Pharmaceuticals Inc
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Admission 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
BlockListing 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Circular 0
No items for this category on selected date.
ClinicalTrial 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
DirectorateChange 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Dividend 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 1
RYTM 08:09
Rhythm Pharmaceuticals Inc
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
Form83 0
No items for this category on selected date.
GeneralMeeting 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
IssueOfEquity 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
MonthlyFactsheet 0
No items for this category on selected date.
NAV 0
No items for this category on selected date.
NameChange 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
OwnShares 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
ProfitWarning 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Prospectus 0
No items for this category on selected date.
Reports 1
RYTM 09:11
Rhythm Pharmaceuticals Inc
Rhythm Reports Positive Preliminary Phase 2 Data For Setmelanotide In Treating Prader-Willi
Results 3
RYTM 12:22
Rhythm Pharmaceuticals Inc
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
SchemeOfArrangement 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
TVR 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
US News 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 14
RYTM 12:22
Rhythm Pharmaceuticals Inc
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
RYTM 12:37
Rhythm Pharmaceuticals Inc
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
RYTM 14:30
Rhythm Pharmaceuticals Inc
Intel Stock and 3 Other Winners I Found Using Barchart’s High-Octane Stock Screener
RYTM 13:15
Rhythm Pharmaceuticals Inc
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder?
RYTM 08:09
Rhythm Pharmaceuticals Inc
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
RYTM 12:58
Rhythm Pharmaceuticals Inc
The Battle Against Genetic Obesity Just Sent This Biotech Stock Flying
RYTM 09:11
Rhythm Pharmaceuticals Inc
Rhythm Reports Positive Preliminary Phase 2 Data For Setmelanotide In Treating Prader-Willi
RYTM 11:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
RYTM 11:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
RYTM 19:01
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
RYTM 01:10
Rhythm Pharmaceuticals Inc
How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Updating Its Bardet-Biedl Diagnosis Algorithm

Today's AI

RYTM · Agentic Market Intelligence

RYTM intelligence is listening.

The engine is monitoring news, price structure, forecasts and financial changes. New scored evidence will appear here against this stock automatically.

Live catalyst scoringAI price pathsRisk-aware triggersFinancial blend
AI bias0.0
Bullish0
Bearish0
Today's AI Starts With News

1 live catalyst is opening Today’s AI for RYTM.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-08-31 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
Rhythm Pharmaceuticals Inc has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
12:22 Today's Catalyst Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Single-Ticker Today's AI
RYTM signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for Rhythm Pharmaceuticals Inc. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full RYTM Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for RYTM on 2026-08-31.

Fundamentals Matrix

About Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

🌐 Visit Official Website ↗

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
7.8B
Enterprise Value
7.6B
Public Float
81.2
Broker Target
139.4667
Shares Out
68.6M
Long Interest
99
Short Interest
1
Exchange
NASDAQ
Currency Code
USD
ISIN
US76243J1051
Ex-Dividend
-
Yield
0.00%
Dividend Rate
-
EPS
-3.13
Market
NASDAQ
Standard Lists
Not currently ranked
Sector
Pharmaceuticals and BiotechnologyUS fundamentals
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for RYTM.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-08-31 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
Rhythm Pharmaceuticals Inc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
12:22 Today's Alert Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
192.2M
Cash
54.3M
EPS
-3.13
Net Income
-196.5M
Revenue
217.2M
Enterprise Value
7.6B
Trailing PE
-
Forward PE
-
Price Sales TTM
35.7553
Price Book MRQ
63.718
EV Revenue
35.039
EV EBITDA
-12.6462
Financial Forecastist

Improving financial engine

Revenue is accelerating +83.8% against the prior comparable period. Net margin is expanding by 58.8 pts. Net debt is coming down +261.6%.

Revenue +83.8% Net Income +12.4% FCF +9.5% Current Ratio 4.17x Forward Rev 79.0M
Improving
Quarter Revenue
60.1M
+83.8%
vs prior comparable quarter
Net Margin
-92.6%
+58.8 pts
profitability pulse
Free Cash Flow
-44.2M
+9.5%
cash conversion
Net Debt / EBITDA
-3.3x
-261.6%
lower is cleaner
Revenue Engine

Latest quarter printed 60.1M with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at -55.6M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 62.1M while net debt is 164.9M. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
50.7M
Revenue Path
-0.73
EPS / Earnings
Growth cue -0.0%
Q1 2026
Consensus
56.1M
Revenue Path
-0.86
EPS / Earnings
Growth cue -0.1%
Q2 2026
Consensus
67.5M
Revenue Path
-0.84
EPS / Earnings
Growth cue -0.1%
Q3 2026
Consensus
79.0M
Revenue Path
-0.83
EPS / Earnings
Growth cue -0.0%
FY 2026
Consensus
298.1M
Revenue Path
-3.26
EPS / Earnings
Growth cue -0.0%
FY 2027
Consensus
539.2M
Revenue Path
-0.74
EPS / Earnings
Growth cue +0.8%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 60.1M -55.6M -44.2M 164.9M
Q4 2025 57.3M -47.5M -26.3M 192.2M
Q3 2025 51.3M -52.9M -26.6M 98.9M
Q2 2025 48.5M -46.6M -23.3M 123.9M
Q1 2025 32.7M -49.5M -40.4M -102.0M
Q4 2024 41.8M -43.3M -18.8M -85.2M

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 189.8M -196.5M -174.1M -116.6M
FY 2024 130.1M -260.6M -238.1M -113.9M
FY 2023 77.4M -184.7M -168.5M -136.2M
FY 2022 23.6M -181.1M -174.2M -177.7M
FY 2021 3.2M -68.0M -168.9M -151.4M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend runway open

Price is 81.1% through the 52-week range, +21.9% vs 50DMA and +15.2% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend runway open Institutional gravity Moderate income rhythm As Of 2026-07-07
Balanced Structure
Structure Score
73.0 / 100
Balanced Structure
Trend Stack
+21.9% / +15.2%
vs 50DMA / 200DMA
52W Position
81.1%
auction position inside the yearly range
Ownership Lock
100.0%
109.9% institutions | 77.0% insiders
Pressure Pocket
11.8% short float
Short ratio 12.8x | monthly +119.2%
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 113.20 with the stock +21.9% vs 50DMA and +15.2% vs 200DMA. The tape is sitting 81.1% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 109.9% and insiders about 77.0%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.

Pressure Pocket

Short pressure is running near 11.8% of float with short ratio 12.8x and monthly change +119.2%. That gives us a read on whether the tape is clean, crowded, or coiled.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
113.20
derived from market cap / shares
52W High
122.20
upper auction edge
52W Low
74.50
lower auction edge
Beta
1.88
volatility character
Shares Out
68.6M
fully diluted count
Shares Float
55.7M
tradable register
Shares Short
8.0M
borrowed stock
Short Ratio
12.8x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
-
split date not supplied

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
109.1485
Institutions As Of
2026-05-31
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
40
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data · RYTM · Last 30 Days

Short D · 12/26 EMA spread with 9 signal

Red histogram bars show short loading accelerating. Green bars show short covering accelerating. The two lines expose the crossover before the raw holder table does.

Short D waiting

Building RYTM short-momentum read

Short D compares the ticker’s disclosed short-position momentum with its own signal line.

Short D—
Signal—
Momentum—

Declared Short Holders

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for RYTM, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-08-31 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
Rhythm Pharmaceuticals Inc has fresh news flow live now, so the tape is framing the chart workspace below.
12:22 Today's Catalyst Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results?
AI Charts Studio
RYTM Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-08-31 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
AI AutoDetection Automatic bull / bear chart read
Detected market structure
Analysing selected range
Why this call
Waiting for sufficient price history.
Invalidation
—
Updates with the timeframe.
Bull caseCalculating upside confirmation.
Bear caseCalculating downside confirmation.
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast